EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Use of pharmacogenetic testing to optimize treatment in patients with alcohol withdrawal syndrome complicated by seizures: a randomized controlled pilot trial

Valentin Yu. Skryabin, Svetlana I. Sokolova, Valentina A. Ivanchenko, Alla A. Matskevich, Anton V. Masyakin

Psychopharmacology and Addiction Biology · 21.07.2026 · 17 (2) · 95-106

DOI: 10.17816/phbn708080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychopharmacology and Addiction Biology, online erschienen am 21.07.2026. Verfasst von Valentin Yu. Skryabin und 4 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Alcohol withdrawal syndrome complicated by seizures requires rapid symptom control while preventing excessive sedation and other dose-dependent adverse drug reactions. The role of pharmacogenetic support in the treatment of such patients remains understudied. AIM: To evaluate whether the use of pharmacogenetic testing results is associated with less severe alcohol withdrawal syndrome in the first 72 hours of treatment and better treatment tolerability compared with standard empirical tactics in hospitalized patients with alcohol withdrawal syndrome complicated by seizures. METHODS: A randomized, controlled pilot trial was conducted in 60 hospitalized patients with alcohol withdrawal syndrome with seizures (International Classification of Diseases, 10th Revision: F10.31). Patients were randomized 1:1 into a pharmacogenetically guided treatment group or a control group. Pharmacogenetic testing was performed at admission for all patients. In the main group, attending physicians received genuine pharmacogenetic reports; in the control group, physicians were provided neutral reports of identical format specifying wild-type genotypes at all tested loci and standard drug dosages. The primary endpoint was the area under the CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, revised) score–time curve (AUC CIWA-Ar) over the first 72 hours. Secondary endpoints included time to clinical stabilization, need for additional therapy correction, length of hospitalization, tolerability on the UKU (UKU Side Effect Rating Scale), and clinically significant adverse events. RESULTS: Mean AUC CIWA-Ar over 72 hours was lower in the main group: 790 ± 175 vs 905 ± 185 score·h (p = 0.032). Nonparametric sensitivity analysis confirmed the direction and significance of the effect. A mixed model for repeated measures revealed a significant interaction of the factors group × time with significant between-group differences at 48 and 72 hours. The main group also demonstrated earlier clinical stabilization, lower need for additional therapy correction, shorter hospitalization, lower total UKU scores, and fewer clinically significant adverse events. CONCLUSION: Pharmacogenetic support of therapy in hospitalized patients with alcohol withdrawal syndrome complicated by seizures was associated with more favorable early clinical dynamics and better treatment tolerability. The pilot nature of the trial requires confirmation of these findings in larger studies.

Zitieren

APA

Skryabin, V. Y., Sokolova, S. I., Ivanchenko, V. A., Matskevich, A. A., & Masyakin, A. V. (2026). Use of pharmacogenetic testing to optimize treatment in patients with alcohol withdrawal syndrome complicated by seizures: a randomized controlled pilot trial. Psychopharmacology and Addiction Biology, 17(2), 95-106. https://doi.org/10.17816/phbn708080

Vancouver

Skryabin VY, Sokolova SI, Ivanchenko VA, Matskevich AA, Masyakin AV. Use of pharmacogenetic testing to optimize treatment in patients with alcohol withdrawal syndrome complicated by seizures: a randomized controlled pilot trial. Psychopharmacology and Addiction Biology. 2026;17(2):95-106. doi:10.17816/phbn708080

BibTeX
@article{Skryabin2026,
  author = {Skryabin, Valentin Yu. and Sokolova, Svetlana I. and Ivanchenko, Valentina A. and Matskevich, Alla A. and Masyakin, Anton V.},
  title = {Use of pharmacogenetic testing to optimize treatment in patients with alcohol withdrawal syndrome complicated by seizures: a randomized controlled pilot trial},
  journal = {Psychopharmacology and Addiction Biology},
  year = {2026},
  volume = {17},
  number = {2},
  pages = {95--106},
  doi = {10.17816/phbn708080}
}
Kostenlos starten →